基于关联规则的血塞通注射液致药品不良反应发生规律的研究
|
摘要
目的:探索血塞通注射液致药品不良反应(adverse drug reaction,ADR)的流行病学特点。方法:系统检索1979—2015年中国期刊全文数据库、中文科技期刊数据库、中文生物医学期刊数据库和万方数据库,收集血塞通注射液致ADR的详细个案报告,采用Microsoft ACCESS软件构建数据库,以Clementine 12.0软件为数据挖掘平台,应用关联规则Apriori算法开展数据挖掘研究。结果:共搜索符合纳入条件的血塞通注射液致ADR的详细个案108例,与ADR相关的字段包括患者年龄段、ADR发生时间段、原发疾病类别和配液浓度。关联规则Apriori算法中置信度最高的规则为"临床配液种类为葡萄糖注射液、配液用量为250 ml且临床给药途径为静脉滴注的患者占总体研究的31.48%,其中91.18%的案例的配液浓度为5%"。结论:血塞通注射液致ADR的发生是在临床用药因素、患者体质因素和药品自身因素共同作用下的复杂表现,其发生规律尚需大样本量的数据分析验证。
OBJECTIVE: To probe into the epidemiological characteristics of adverse drug reactions( ADR)induced by Xuesaitong injection. METHODS: Case reports on ADR induced by Xuesaitong injection during 1979-2015 were collected by retrieving CNKI,VIP,CBM and Wanfang,Microsoft ACCESS was adopted to construct database,and the Clementine 12. 0 was set as the platform to perform data mining with the application of Apriori algorithm.RESULTS: A total of 108 cases of ADR induced by Xuesaitong injection were selected to be matched with the including criteria,ADR related fields including patients ' genders,ages,occurrence time of ADR,categories of primary diseases and the concentration of dosing fluid. Apriori algorithm indicated that the rule with the highest confidence degree was "the cases with the dosing fluid of glucose injection,dosage of 250 ml and administration route of intravenous drip accounted for 31. 48% of the total cases,of which 91. 18% with the concentration of dosing fluid of 5% ". CONCLUSIONS: ADR induced by Qingkailing injection is a complicated result caused under the combined effects of factors of clinical medication,patients ' physical condition and the nature of drugs,yet its occurrence regularities still needs analysis and verification with the data of larger sample size.
OBJECTIVE: To probe into the epidemiological characteristics of adverse drug reactions( ADR)induced by Xuesaitong injection. METHODS: Case reports on ADR induced by Xuesaitong injection during 1979-2015 were collected by retrieving CNKI,VIP,CBM and Wanfang,Microsoft ACCESS was adopted to construct database,and the Clementine 12. 0 was set as the platform to perform data mining with the application of Apriori algorithm.RESULTS: A total of 108 cases of ADR induced by Xuesaitong injection were selected to be matched with the including criteria,ADR related fields including patients ' genders,ages,occurrence time of ADR,categories of primary diseases and the concentration of dosing fluid. Apriori algorithm indicated that the rule with the highest confidence degree was "the cases with the dosing fluid of glucose injection,dosage of 250 ml and administration route of intravenous drip accounted for 31. 48% of the total cases,of which 91. 18% with the concentration of dosing fluid of 5% ". CONCLUSIONS: ADR induced by Qingkailing injection is a complicated result caused under the combined effects of factors of clinical medication,patients ' physical condition and the nature of drugs,yet its occurrence regularities still needs analysis and verification with the data of larger sample size.
引文
[1]吴嘉瑞,张冰.中药注射剂不良反应与安全应用[M].北京:中国中医药出版社,2012:1-518.
[2]黎涛,林昊.广西地区486例血塞通注射液不良反应探讨[J].北方药学,2015,12(6):139,101.
[3]李琼.中药注射剂临床合理应用[J].内蒙古中医药,2017,36(2):105-106.
[4]徐厚明,倪俊杰.225例中药注射剂致过敏性休克病例分析[J].中国新药杂志,2010,19(21):2012-2015.
[5]李继友,刘雅嫔.祛瘀中药注射剂致过敏性休克病例分析[J].药学与临床研究,2013,21(6):686-688.
[6]罗治华,蒋三员,张健民.心脑血管病常用中药针剂的不良反应分析[J].中国药物与临床,2002,2(6):412-413.
[7]李丽.中药注射剂不良反应报告分析[J].中成药,2003,25(10):319.
[8]常建勋.血塞通注射液不良反应、不良事件回顾性分析[J].西部中医药,2014,27(7):48-51.
[9]李有林.血塞通注射液不良反应82例回顾性分析[J].中国继续医学教育,2015,7(33):207-208.
[10]黄振,郭玲.血塞通注射液不良反应分析[J].中国医药导报,2010,7(31):116-117.
[11]柳青,雷招宝,赵永波.综合性医院3年94例中药注射剂不良反应报告分析[J].中成药,2009,31(10):1605-1607.
[12]孙承浩.血塞通注射液致过敏性休克3例不良反应案例分析[J].海峡学,2014,26(11):263-264.
[13]李文武,张惠霞,杨莎莎,等.631例血塞通注射液不良反应/事件报告分析[J].中国药物警戒,2010,7(11):690-693.
[14]董红斌.27例血塞通注射液不良反应分析[J].临床医学,2013,33(9):123.
[15]张建民,雷招宝.血塞通与血栓通注射剂致过敏性休克的特点与合理用药[J].中成药,2015,37(8):1869-1872.
[16]王景亮.血塞通注射液不良反应分析及预防措施[J].中国处方药,2016,14(12):49-50.
[17]谢奕如,汤丹灵,蓝焜初.中药注射剂致过敏性休克132例文献分析[J].光明中医,2008,23(10):1607-1608.
[18]陈颖.中药注射液不良反应监测结果分析[J].吉林医学,2014,35(11):2374-2375.
[19]和慧秋.浅谈血塞通注射剂不良反应与防范对策[J].中国民族民间医药,2014,23(19):80-81.
[20]傅唐德.中药注射剂配伍存在问题与处置思维[J].临床合理用药杂志,2009,2(21):7.
[21]柳青,雷招宝,赵永波.综合性医院3年94例中药注射剂不良反应报告分析[J].中成药,2009,31(10):1605-1607.
[22]雷光远,雷招宝.血塞通注射液不良反应36例回顾性分析[J].中成药,2010,32(5):851-853.
[23]万雄飞.68例血塞通注射液致不良反应文献分析[J].中国医院用药评价与分析,2013,13(9):846-848.
[2]黎涛,林昊.广西地区486例血塞通注射液不良反应探讨[J].北方药学,2015,12(6):139,101.
[3]李琼.中药注射剂临床合理应用[J].内蒙古中医药,2017,36(2):105-106.
[4]徐厚明,倪俊杰.225例中药注射剂致过敏性休克病例分析[J].中国新药杂志,2010,19(21):2012-2015.
[5]李继友,刘雅嫔.祛瘀中药注射剂致过敏性休克病例分析[J].药学与临床研究,2013,21(6):686-688.
[6]罗治华,蒋三员,张健民.心脑血管病常用中药针剂的不良反应分析[J].中国药物与临床,2002,2(6):412-413.
[7]李丽.中药注射剂不良反应报告分析[J].中成药,2003,25(10):319.
[8]常建勋.血塞通注射液不良反应、不良事件回顾性分析[J].西部中医药,2014,27(7):48-51.
[9]李有林.血塞通注射液不良反应82例回顾性分析[J].中国继续医学教育,2015,7(33):207-208.
[10]黄振,郭玲.血塞通注射液不良反应分析[J].中国医药导报,2010,7(31):116-117.
[11]柳青,雷招宝,赵永波.综合性医院3年94例中药注射剂不良反应报告分析[J].中成药,2009,31(10):1605-1607.
[12]孙承浩.血塞通注射液致过敏性休克3例不良反应案例分析[J].海峡学,2014,26(11):263-264.
[13]李文武,张惠霞,杨莎莎,等.631例血塞通注射液不良反应/事件报告分析[J].中国药物警戒,2010,7(11):690-693.
[14]董红斌.27例血塞通注射液不良反应分析[J].临床医学,2013,33(9):123.
[15]张建民,雷招宝.血塞通与血栓通注射剂致过敏性休克的特点与合理用药[J].中成药,2015,37(8):1869-1872.
[16]王景亮.血塞通注射液不良反应分析及预防措施[J].中国处方药,2016,14(12):49-50.
[17]谢奕如,汤丹灵,蓝焜初.中药注射剂致过敏性休克132例文献分析[J].光明中医,2008,23(10):1607-1608.
[18]陈颖.中药注射液不良反应监测结果分析[J].吉林医学,2014,35(11):2374-2375.
[19]和慧秋.浅谈血塞通注射剂不良反应与防范对策[J].中国民族民间医药,2014,23(19):80-81.
[20]傅唐德.中药注射剂配伍存在问题与处置思维[J].临床合理用药杂志,2009,2(21):7.
[21]柳青,雷招宝,赵永波.综合性医院3年94例中药注射剂不良反应报告分析[J].中成药,2009,31(10):1605-1607.
[22]雷光远,雷招宝.血塞通注射液不良反应36例回顾性分析[J].中成药,2010,32(5):851-853.
[23]万雄飞.68例血塞通注射液致不良反应文献分析[J].中国医院用药评价与分析,2013,13(9):846-848.